Progressive facial disease in a patient on long-term TNF-α blockade
A 56-year-old man in Norway developed an indolent but destructive facial illness over two years before the diagnosis finally pointed away from bacterial cellulitis and toward mucocutaneous leishmaniasis. His history made the presentation especially consequential: he had lived in Norway all his life and had been treated for seropositive rheumatoid arthritis with methotrexate for 15 years and infliximab for 11 years. The combination of prolonged immunomodulation and slowly progressive mucosal involvement created a clinical setting in which an unusual parasitic infection could masquerade as a routine bacterial process for far too long.
The presenting features were striking in their persistence rather than their intensity. Progressive erythema, swelling, crusting, and epistaxis affected the right ear, nose, and cheek, with the process extending across a cosmetically and functionally sensitive region of the face. Repeated courses of oral and intravenous anti-staphylococcal antibiotics had already been given for presumed facial cellulitis, yet the lesions continued to advance. Superficial cultures repeatedly yielded Staphylococcus aureus and Streptococcus agalactiae, a result that could easily have reinforced the bacterial diagnosis even as the overall clinical picture refused to fit it. Persistently normal inflammatory markers deepened the mismatch between the presumed diagnosis and the actual disease biology.
The case exposes a familiar diagnostic trap in immunosuppressed patients: colonization or secondary infection can obscure the primary driver of tissue injury. In chronic facial lesions, especially when crusting and discharge are present, superficial swabs may recover organisms that are present on damaged skin without explaining the underlying pathology. In this setting, the lack of response to broad anti-staphylococcal therapy carried more diagnostic weight than the cultures themselves. A parasitic infection that infiltrates skin and mucosa can smolder with surprisingly limited systemic inflammation, particularly when host immunity has been altered by long-term TNF-α inhibitor therapy.
Why leishmaniasis belongs in the differential here
Leishmania species are intracellular protozoa, and control of infection depends heavily on intact cell-mediated immunity. Blocking tumor necrosis factor-α can compromise the host response that normally helps contain these organisms, allowing latent infection to emerge or new infection to progress in a more aggressive or atypical manner. The clinical consequences are particularly important in mucocutaneous disease, where involvement of the nose and adjacent facial structures can produce crusting, bleeding, swelling, and deformity before the correct diagnosis is recognized. In a patient from a non-endemic country, the organism may not be the first diagnostic consideration, which makes the immune history even more central to bedside reasoning.
The case also shows how misleading chronicity can be. Two years of symptoms may suggest a smoldering inflammatory dermatosis, chronic bacterial infection, vasculitis, or even malignancy, depending on the appearance and location of the lesions. Yet the combination of persistent progression, absent inflammatory response, and failure of repeated antibacterial regimens should force a wider infectious differential. Facial disease involving the nose is especially concerning because epistaxis and crusting can reflect mucosal destruction rather than simple superficial dermatitis. Once the mucosa is involved, the threshold for pursuing tissue diagnosis should be low.
A single sentence captures the danger here: repeated antibiotics did not stop the process.
Immunosuppression, culture results, and the cost of anchoring
This presentation illustrates how easily clinicians can anchor on a positive surface culture when the culture grows organisms commonly associated with skin and soft tissue infection. In chronic ulcerated or crusted lesions, however, those findings may represent superinfection or colonization layered on top of a different primary process. Normal inflammatory markers should not be taken as reassurance when the lesion is steadily worsening under treatment. They may instead signal a pathobiology that is localized, atypical, or driven by a pathogen that does not provoke the expected acute-phase response.
Infliximab likely played a central permissive role in the course, and the duration of exposure matters. Eleven years of anti-TNF therapy is a long window for opportunistic infection risk to accumulate, especially when paired with methotrexate and a chronic autoimmune disease. Rheumatoid arthritis itself can complicate interpretation, because immunosuppressed patients often enter care with overlapping inflammatory, infectious, and treatment-related explanations already in play. When the face is involved and the lesion is not behaving like cellulitis, tissue sampling becomes more than a confirmatory step; it becomes the decisive move that can redirect the entire diagnostic pathway.
Bedside lessons from a non-endemic infection in northern Europe
This case is clinically important because it breaks the false comfort of geography. A lifelong resident of Norway still developed a disease classically associated with other settings, and the immune state likely mattered more than birthplace. For clinicians, that means travel history is helpful but not sufficient. Biologic therapy can shift the infectious risk profile enough that diseases once considered unlikely in a given region become plausible again, especially when the presentation is chronic, destructive, and refractory to standard antibacterial therapy.
The anatomy of the lesion should also sharpen suspicion. Ear, nose, and cheek involvement with crusting and epistaxis points toward a process capable of involving skin and mucosa together, not merely a superficial bacterial cellulitis. The fact that the process persisted despite intravenous antibiotics should prompt early consideration of tissue-based diagnosis, including histopathology and targeted microbiologic testing. In immunosuppressed patients, superficial microbiology alone rarely settles the question.
The clinical picture here is not just an unusual diagnosis. It is a reminder that prolonged TNF-α inhibitor exposure can change the shape of infectious disease at the bedside, converting a geographically unexpected protozoal infection into a prolonged, misdirected treatment course. The cost of that delay is not theoretical: the lesions continued to progress while the wrong organism was being treated, and the nose was already involved when the diagnosis came into view. Future management questions in similar patients center on how quickly clinicians can move from surface cultures to tissue diagnosis when the clinical course no longer matches cellulitis.